CCL2-CCR2信号轴在肝脏疾病中的作用：机制和治疗靶向

赵 才发1, 任 宾2
1、青海大学研究生院
2、青海大学附属医院肝胆胰外科

摘要


肝脏疾病包括感染、肝硬变和肿瘤等常见或重要的疾病。肝细胞癌（HCC）是全球癌症死亡的第三大原
因，趋化因子配体CCL2及其受体CCR2在炎症、免疫反应和癌症发展中起着重要作用。通过与CCR2相互作用，
CCL2促进癌细胞迁移并将免疫抑制细胞募集到肿瘤微环境中，从而促进癌症发展。本文综述了CCL2-CCR2信
号转导轴肝脏疾病发生中的作用，重点介绍了近年来CCL2-CCR2靶向治疗的研究，重点关注临床前研究和临床
试验。

关键词


CCL2/CCR2轴；肝脏疾病；巨噬细胞

全文:

PDF


参考


[1]CRAIG M J, LOBERG R D. CCL2 (Monocyte

Chemoattractant Protein-1) in cancer bone metastases[J/

OL]. Cancer and Metastasis Reviews, 2007, 25(4): 611-619.

DOI:10.1007/s10555-006-9027-x.[2]TENG K Y, HAN J, ZHANG X. Blocking the

CCL2-CCR2 axis using CCL2 neutralizing antibody is

an effective therapy for hepatocellular cancer in a mouse

model[J/OL]. Molecular cancer therapeutics, 2017, 16(2):

312-322. DOI:10.1158/1535-7163.MCT-16-0124.

[3]YAO W, BA Q, LI X. A Natural CCR2 Antagonist

Relieves Tumor-associated Macrophage-mediated

Immunosuppression to Produce a Therapeutic Effect for Liver

Cancer[J/OL]. EBioMedicine, 2017, 22: 58. DOI:10.1016/

j.ebiom.2017.07.014.

[4]CHE L, YUAN Y H, JIA J, Activation of sonic

hedgehog signaling pathway is an independent potential

prognosis predictor in human hepatocellular carcinoma

patients[J/OL]. Chinese Journal of Cancer Research, 2012,

24(4): 323-331. DOI:10.3978/j.issn.1000-9604.2012.10.10.

[5]ZHUANG H, CAO G, KOU C. CCL2/CCR2 axis

induces hepatocellular carcinoma invasion and epithelialmesenchymal transition in vitro through activation of the

Hedgehog pathway[J/OL]. Oncology Reports, 2018, 39(1):

21-30. DOI:10.3892/or.2017.6069.

[6]FRIDLENDER Z G, BUCHLIS G, KAPOOR V

CCL2 Blockade Augments Cancer Immunotherapy[J/OL].

Cancer research, 2010, 70(1): 109. DOI:10.1158/0008-5472.

CAN-09-2326.

[7]HAO Q, VADGAMA J V, WANG P. CCL2/CCR2

signaling in cancer pathogenesis[J/OL]. Cell Communication

and Signaling : CCS, 2020, 18: 82. DOI:10.1186/s12964-

020-00589-8.

[8]CHUN E, LAVOIE S, MICHAUD M. CCL2

Promotes Colorectal Carcinogenesis by Enhancing

Polymorphonuclear Myeloid-Derived Suppressor Cell

Population and Function[J/OL]. Cell reports, 2015, 12(2):

244-257. DOI:10.1016/j.celrep.2015.06.024.

[9]LOBERG R D, YING C, CRAIG M. CCL2

as an Important Mediator of Prostate Cancer Growth In

Vivo through the Regulation of Macrophage Infiltration[J].

Neoplasia (New York, N.Y.), 2007, 9(7): 556-562.

[10]ZHU X, FUJITA M, SNYDER L A. Systemic

Delivery of Neutralizing Antibody Targeting CCL2 for

Glioma Therapy[J/OL]. Journal of neuro-oncology, 2011,

104(1): 83-92. DOI:10.1007/s11060-010-0473-5.

[11]TENG K Y, HAN J, ZHANG X. Blocking the

CCL2-CCR2 axis using CCL2 neutralizing antibody is

an effective therapy for hepatocellular cancer in a mouse

model[J/OL]. Molecular cancer therapeutics, 2017, 16(2):

312-322. DOI:10.1158/1535-7163.MCT-16-0124.

[12]IOANNOU G N. HCC surveillance after SVR in

patients with F3/F4 fibrosis[J/OL]. Journal of Hepatology,

2021, 74(2): 458-465. DOI:10.1016/j.jhep.2020.10.016.

[13]DERMANI F K, SAMADI P, RAHMANI G.

PD-1/PD-L1 immune checkpoint: Potential target for

cancer therapy[J/OL]. Journal of Cellular Physiology, 2019,

234(2): 1313-1325. DOI:10.1002/jcp.27172.

[14]MANTOVANI A, SOZZANI S, LOCATI M.

Macrophage polarization: tumor-associated macrophages

as a paradigm for polarized M2 mononuclear phagocytes[J/

OL]. Trends in Immunology, 2002, 23(11): 549-555.

DOI:10.1016/S1471-4906(02)02302-5.

[15]YANG H, ZHANG Q, XU M CCL2-CCR2

axis recruits tumor associated macrophages to induce

immune evasion through PD-1 signaling in esophageal

carcinogenesis[J/OL]. Molecular Cancer, 2020, 19: 41.

DOI:10.1186/s12943-020-01165-x.

[16]Colony-stimulating factor-1-induced AIF1

expression in tumor-associated macrophages enhances the

progression of hepatocellular carcinoma - PMC[EB/OL].

[2024-03-07].

[17]Distinct functions of senescence-associated immune

responses in liver tumor surveillance and tumor progression.

[18]MOISAN F, FRANCISCO E B, BROZOVIC A.

Enhancement of paclitaxel and carboplatin therapies by CCL2

blockade in ovarian cancers[J/OL]. Molecular Oncology,

2014, 8(7): 1231-1239. DOI:10.1016/j.molonc.2014.03.016.

[19]KASPER M, REGL G, FRISCHAUF A M. GLI

transcription factors: Mediators of oncogenic Hedgehog

signalling[J/OL]. European Journal of Cancer, 2006, 42(4):

437-445. DOI:10.1016/j.ejca.2005.08.039.

[20]Functional and genetic deconstruction of the cellular

origin in liver cancer | Nature Reviews Cancer[EB/OL].

[2024-03-06].

[21]Recurrence-free survival after radiofrequency

ablation of hepatocellular carcinoma. A registry report ofthe impact of risk factors on outcome - PubMed[EB/

OL]. [2024-03-07]. https://pubmed.ncbi.nlm.nih.

gov/17766723/.

[22]HUANG W, CHEN Z, ZHANG L Interleukin-8

Induces Expression of FOXC1 to Promote Transactivation

of CXCR1 and CCL2 in Hepatocellular Carcinoma

Cell Lines and Formation of Metastases in Mice[J/

OL]. Gastroenterology, 2015, 149(4): 1053-1067.e14.

DOI:10.1053/j.gastro.2015.05.058.

[23]CHEN C, HE W, HUANG J. LNMAT1 promotes

lymphatic metastasis of bladder cancer via CCL2 dependent

macrophage recruitment[J/OL]. Nature Communications,

2018, 9: 3826. DOI:10.1038/s41467-018-06152-x.

[24]Macrophage-Derived Cathepsin S Remodels

the Extracellular Matrix to Promote Liver Fibrogenesis -

ScienceDirect[EB/OL]. [2024-03-07].

[25]Monocyte chemotactic protein‐1 (MCP‐1) acts as

a paracrine and autocrine factor for prostate cancer growth

and invasion - Lu - 2006 - The Prostate - Wiley Online

Library[EB/OL]. [2024-02-27].

[26]LI Q, LIU Z, XU M, PCAF inhibits hepatocellular

carcinoma metastasis by inhibition of epithelial-mesenchymal

transition by targeting Gli-1[J/OL]. Cancer Letters, 2016,

375(1): 190-198. DO

[27]Original article: Targeting both tumour-associated

CXCR2+ neutrophils and CCR2+ macrophages disrupts

myeloid recruitment and improves chemotherapeutic

responses in pancreatic ductal adenocarcinoma - PMC[EB/

OL]. [2024-03-06]. https://www.ncbi.nlm.nih.gov/pmc/

articles/PMC5969359/.

[28]ZHANG J, LU Y, PIENTA K J. Multiple Roles

of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate

Cancer Growth[J/OL]. JNCI Journal of the National Cancer

Institute, 2010, 102(8): 522-528. DOI:10.1093/jnci/djq044.

[29]何虹霖.趋化因子CCL2及其受体CCR2，以及

钙离子结合蛋白S100A11，S100A6调节肝脏再生功能的

实验研究[D/OL].

[30]张夏鼎.趋化因子CCL28在原发性肝细胞癌发生

发展过程中的作用研究[D/OL]. DOI：10.27169/d.cnki.

gwqgu.2022.001805.

[31]CXCL5过表达介导中性粒细胞浸润，提示肝细

胞癌预后不良-PubMed[EB/OL].[2024-09-02].


Refbacks

  • 当前没有refback。